Genomic medicine
Advances in genetic technologies and in the understanding of clinically relevant genetic variation are revolutionising how a whole range of diseases can be diagnosed and treated. This collection of articles offers a glimpse into research that is laying important groundwork for genomic medicine to play a transformative part in patient healthcare. The selected articles explore new approaches to prevent infectious disease, treat cancer and, potentially, cure inherited disorders using knowledge of the genome.
This Collection is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge the financial support Danaher in producing the collection.
Danaher believes that, in the next decade, genomic medicines will foster “Generation Cure,” a new future for healthcare, in which personalized and precision medicines will be mainstream treatments.
Through its Life Sciences and Diagnostics companies, Danaher is committed to accelerating cures and transforming medicine. They are doing this by providing scientists and physicians with the specialized tools and know-how to develop a greater breadth of genomic medicines at scale. They are creating fit-for-purpose manufacturing processes designed for genomic medicines, beyond re-engineering those designed for small-molecule and biologic modalities. They are working with researchers, drug developers and manufacturers to break down silos and collaborating to sustainably compress manufacturing timescales and increasing efficiencies.
Multiple companies within the Danaher Corporation (NYSE:DHR) are among leaders in the industry focused on accelerating cures with genomic medicine. Cytiva, Pall Corporation, Precision NanoSystems, Integrated DNA Technologies and Aldevron are heavily involved in the discovery and development of research and manufacturing components, intermediates and services for genomic medicines. IDBS, Beckman Coulter Life Sciences, Leica Microsystems, Molecular Devices, Phenomenex, and SCIEX are focused on tools, instruments and software to advance genomic medicines through drug pipelines from research to patients in need. Our companies strive every day to arm physicians and scientists in the fight against disease, from enabling next generation sequencing to supplying synthetic DNA/RNA, all the way through biomanufacturing of therapeutics and vaccines.
